Johnson & Johnson, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Gerberry from Bank of America Securities reiterated a Hold rating on the stock and has a $220.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason Gerberry has given his Hold rating due to a combination of factors that reflect a balanced risk-reward profile for Johnson & Johnson. The company is valued with a premium-sector multiple, which is justified by its growth prospects and asset mix. However, the potential for further stock re-rating seems limited due to a lack of significant pipeline catalysts and uncertainty regarding upward revisions in earnings estimates.
In the fiscal year 2026, Johnson & Johnson is expected to maintain mid-single-digit growth, driven by products like Darzalex and MedTech, while facing challenges from the Stelara loss of exclusivity. Although there are upcoming product launches and pipeline developments, such as Caplyta for depression and icotrokinra for psoriasis, these are not anticipated to significantly impact the company’s financial performance in the near term. The anticipated data releases from the pipeline, including Milvexian and bispecific programs, are not expected to provide major breakthroughs that would warrant a change in the current stock rating.
In another report released on December 12, Morgan Stanley also maintained a Hold rating on the stock with a $197.00 price target.